Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CXCR1 | P25024 | 2/20 | 0.38 |
| ▸ | CXCR2 | P25025 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1713633 | 0.87 | HCAR3 (0.55) | ALDH1A1HCAR3KDM4EALOX15HSD17B10 | |
| Hydrochloric Acid SCHEMBL2821116 | 0.86 | HCAR3 (0.54) | ALDH1A1HCAR3KDM4EALOX15HSD17B10 | |
| SCHEMBL27810972 | 0.86 | HCAR3 (0.54) | ALDH1A1HCAR3KDM4EALOX15HSD17B10 | |
| SCHEMBL2706310 | 0.83 | ALDH1A1 (0.46) | ALDH1A1HCAR3HDAC6CXCR1CXCR2 | |
| SCHEMBL250023 | 0.83 | MAPK1 (0.56) | KMT2AALDH1A1MEN1HDAC6L3MBTL1 | |
| SCHEMBL6351750 | 0.80 | CA12 (0.47) | KMT2AALDH1A1MEN1MAPTNPC1 | |
| SCHEMBL31098145 | 0.79 | KCNJ1 (0.45) | KMT2AMEN1HCAR3KCNJ1L3MBTL1 | |
| SCHEMBL14023317 | 0.79 | KCNJ1 (0.45) | KMT2AHCAR3KCNJ1L3MBTL1GAA | |
| SCHEMBL2749675 | 0.79 | KCNJ1 (0.45) | KMT2AMEN1HCAR3KCNJ1L3MBTL1 | |
| SCHEMBL12639886 | 0.77 | KCNJ1 (0.44) | KMT2AALDH1A1HCAR3KCNJ1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | disclosed |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2018-08-09 | — | — | US | disclosed |
| US-9968554-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2018-05-15 | — | — | US | disclosed |
| US-20140356417-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-12-04 | — | — | US | disclosed |
| US-8790691-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2014-07-29 | — | — | US | disclosed |
| US-8568772-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-29 | — | — | US | disclosed |
| US-8545876-B1 | Modified drugs for use in liposomal nanoparticles | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-01 | — | — | US | disclosed |
| US-8545877-B2 | Modified drugs for use in liposomal nanoparticles | UNIVERSITY OF BRITISH COLUMBIA (CA) | 2013-10-01 | — | — | US | disclosed |
| US-20130236534-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-12 | — | — | US | disclosed |
| US-20130230582-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-05 | — | — | US | disclosed |
| US-20130230583-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | UNIV BRITISH COLUMBIA (CA) | 2013-09-05 | — | — | US | disclosed |
| US-8324410-B2 | Modified drugs for use in liposomal nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-12-04 | — | — | US | disclosed |
| US-20120237591-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2012-09-20 | — | — | US | disclosed |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130230582-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | KMT2A 3264/4885ALDH1A1 1591/4885MEN1 1118/4885 |
| US-20110165225-A1 | Modified Drugs for Use in Liposomal Nanoparticles | ABCB11, SLC47A1, ABCB1 | KMT2A 3758/4885ALDH1A1 1273/4885MEN1 1141/4885 |
| US-20120237591-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | KMT2A 3264/4885ALDH1A1 1591/4885MEN1 1118/4885 |
| US-20130236534-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | KMT2A 3264/4885ALDH1A1 1591/4885MEN1 1118/4885 |
| US-20130230583-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, ABCB1, SLC43A1 | KMT2A 3264/4885ALDH1A1 1591/4885MEN1 1118/4885 |
| US-20180221279-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | KMT2A 3758/4885ALDH1A1 1273/4885MEN1 1141/4885 |
| US-20140356417-A1 | MODIFIED DRUGS FOR USE IN LIPOSOMAL NANOPARTICLES | ABCB11, SLC47A1, ABCB1 | KMT2A 3758/4885ALDH1A1 1273/4885MEN1 1141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.